

REC'D PCT/PTO 21 SEP 2005 PCT #9

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re United States Patent Application of:

Applicant: David Hone

Application No.: 10/525,702

Date Filed: February 18, 2005

Title: RECOMBINANT DOUBLE-STRANDED RNA PHAGES AND USES THEREOF

Docket No.: 4115-178

Examiner: Unassigned

Art Unit: Unassigned

Conf. No.: 4972

Customer No.:

**23448**

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.

Candace White

September 19, 2005

Date of Mailing

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. \_\_\_\_\_ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,

  
Marianne Fuierer  
Reg. No. 39,983  
Attorney for Applicant

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
Telephone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney Ref: 4115-178



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Sheet 1 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AA	Abacioglu, Y.H., Fouts, T.R., Laman, J.D. <i>et al.</i> Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. <i>AIDS Res. Hum. Retrovir.</i> 1994, 10(4), 371-381.	
	AB	Agwale, S.M., Shata, M.T., Reitz, M.S., Jr. <i>et al.</i> A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. <i>Proc Natl Acad Sci U S A</i> 2002, 99(15), 10037-10041.	
	AC	Andre, S., Seed, B., Eberle, J., Schraut, W., Bultmann, A. & Haas, J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. <i>J Virol</i> 1998, 72(2), 1497-1503.	
	AD	Baba, T.W., Liska, V., Hofmann-Lehmann, R. <i>et al.</i> Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. <i>Nat. Med.</i> 2000, 6(2), 200-206.	
	AE	Bagley, K.C., Shata, M.T., Onyabe, D.Y., DeVico, A.L., Fouts, T.R., Lewis, G.K. & Hone, D.M. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. <i>Vaccine</i> 2003, 21, 3335-3341.	
	AF	Balasuriya, U.B., Heidner, H.W., Davis, N.L. <i>et al.</i> Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. <i>Vaccine</i> 2002, 20(11-12), 1609-1617.	
	AG	Bamford, D.H. & Palva, E.T. Structure of the lipid-containing bacteriophage phi 6. Disruption by Triton X-100 treatment. <i>Biochim Biophys Acta</i> 1980, 601(2), 245-259.	
Examiner signature		Date Considered	

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

- 2 Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 2 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AH	Berger, H. & Kennedy, K. Physical measurements on the lipid-containing bacteriophage phi 6. <i>Biochim Biophys Acta</i> 1980, 633(1), 68-76.	
	AI	Berglund, P., Fleeton, M.N., Smerdou, C. & Liljestrom, P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. <i>Vaccine</i> 1999, 17(5), 497-507.	
	AJ	Brinster, C., Chen, M., Boucreux, D. <i>et al.</i> Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. <i>J Gen Virol</i> 2002, 83(Pt 2), 369-381.	
	AK	Caley, I.J., Betts, M.R., Irlbeck, D.M. <i>et al.</i> Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. <i>J Virol</i> 1997, 71(4), 3031-3038.	
	AL	Conley, A.J., Kessler, J.A., II, Boots, L.J. <i>et al.</i> The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. <i>J. Virol.</i> 1996, 70(10), 6751-6758.	
	AM	Conry, R.M., LoBuglio, A.F., Wright, M. <i>et al.</i> Characterization of a messenger RNA polynucleotide vaccine vector. <i>Cancer Res</i> 1995, 55(7), 1397-1400.	
	AN	Dalemans, W., Delers, A., Delmelle, C. <i>et al.</i> Protection against homologous influenza challenge by genetic immunization with SFV-RNA encoding Flu-HA. <i>Ann N Y Acad Sci</i> 1995, 772, 255-256.	
	AO	Davis, N.L., Brown, K.W. & Johnston, R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. <i>J Virol</i> 1996, 70(6), 3781-3787.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 3 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AP	DeVico, A.L., Rahman, R., Welch, J. <i>et al.</i> Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. <i>Virol.</i> 1995, 211(2), 583-588.	
	AQ	Emini, E.A., Schleif, W.A., Nunberg, J.H. <i>et al.</i> Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. <i>Nature</i> 1992, 355(6362), 728-730.	
	AR	Emini, E.A., Nara, P.L., Schleif, W.A. <i>et al.</i> Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. <i>J. Virol.</i> 1990, 64(8), 3674-3678.	
	AS	Fleeton, M.N., Sheahan, B.J., Gould, E.A., Atkins, G.J. & Liljestrom, P. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. <i>J Gen Virol</i> 1999, 80 ( Pt 5), 1189-1198.	
	AT	Fouts, T.R., Lewis, G.K. & Hone, D.M. Construction and characterization of a <i>Salmonella typhi</i> -based human immunodeficiency virus type 1 vector vaccine. <i>Vaccine</i> 1995, 13(6), 561-569.	
	AU	Fouts, T.R., Tuskan, R., Godfrey, K. <i>et al.</i> Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. <i>J Virol</i> 2000, 74(24), 11427-11436.	
	AV	Galan, J.E., Nakayama, K. & Curtiss, R.d. Cloning and characterization of the <i>asd</i> gene of <i>Salmonella typhimurium</i> : use in stable maintenance of recombinant plasmids in <i>Salmonella</i> vaccine strains. <i>Gene</i> 1990, 94(1), 29-35.	
	AW	Gottlieb, P., Strassman, J., Qiao, X., Frilander, M., Frucht, A. & Mindich, L. In vitro packaging and replication of individual genomic segments of bacteriophage phi 6 RNA. <i>J Virol</i> 1992, 66(5), 2611-2616.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 4 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AX	Gottlieb, P., Strassman, J., Frucht, A., Qiao, X.Y. & Mindich, L. In vitro packaging of the bacteriophage phi 6 ssRNA genomic precursors. <i>Virology</i> 1991, 181(2), 589-594.	
	AY	Gottlieb, P., Strassman, J., Qiao, X.Y., Frucht, A. & Mindich, L. In vitro replication, packaging, and transcription of the segmented double-stranded RNA genome of bacteriophage phi 6: studies with procapsids assembled from plasmid-encoded proteins. <i>J Bacteriol</i> 1990, 172(10), 5774-5782.	
	AZ	Gottlieb, P., Metzger, S., Romantschuk, M. <i>et al.</i> Nucleotide sequence of the middle dsRNA segment of bacteriophage phi 6: placement of the genes of membrane-associated proteins. <i>Virology</i> 1988, 163(1), 183-190.	
	BA	Haas, J., Park, E.C. & Seed, B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. <i>Curr Biol</i> 1996, 6(3), 315-324.	
	BB	Haigwood, N.L., Watson, A., Sutton, W.F. <i>et al.</i> Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. <i>Immunol. Lett.</i> 1996, 51(1-2), 107-114.	
	BC	Hofmann-Lehmann, R., Vlasak, J., Rasmussen, R.A. <i>et al.</i> Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. <i>J. Virol.</i> 2001, 75(16), 7470-7480.	
	BD	Hoogstraten, D., Qiao, X., Sun, Y., Hu, A., Onodera, S. & Mindich, L. Characterization of phi8, a bacteriophage containing three double-stranded RNA genomic segments and distantly related to phi6. <i>Virology</i> 2000, 272(1), 218-224.	
	BE	Jang, S.K., Krausslich, H.G., Nicklin, M.J., Duke, G.M., Palmenberg, A.C. & Wimmer, E. A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. <i>J Virol</i> 1988, 62(8), 2636-2643.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 5 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BF	Johnson, M.D., 3rd & Mindich, L. Plasmid-directed assembly of the lipid-containing membrane of bacteriophage phi 6. <i>J Bacteriol</i> 1994, 176(13), 4124-4132.	
	BG	Kakitani, H., Iba, H. & Okada, Y. Penetration and partial uncoating of bacteriophage phi 6 particle. <i>Viol.</i> 1980, 101(2), 475-483.	
	BH	Kang, C.Y., Hariharan, K., Nara, P.L., Sodroski, J. & Moore, J.P. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. <i>J. Virol.</i> 1994, 68(9), 5854-5862.	
	BI	Kieft, J.S., Zhou, K., Jubin, R., Murray, M.G., Lau, J.Y. & Doudna, J.A. The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold. <i>J Mol Biol</i> 1999, 292(3), 513-529.	
	BJ	Kieft, J.S., Zhou, K., Grech, A., Jubin, R. & Doudna, J.A. Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. <i>Nat Struct Biol</i> 2002, 9(5), 370-374.	
	BK	LaCasse, R.A., Follis, K.E., Trahey, M., Scarborough, J.D., Littman, D.R. & Nunberg, J.H. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. <i>Science</i> 1999, 283(5400), 357-362.	
	BL	Mascola, J.R., Lewis, M.G., Stiegler, G. <i>et al.</i> Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. <i>J. Virol.</i> 1999, 73(5), 4009-4018.	
	BM	Mascola, J.R., Stiegler, G., VanCott, T.C. <i>et al.</i> Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. <i>Nat. Med.</i> 2000, 6(2), 207-210.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

- 3 Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 6 of 11

COMPLETE IF KNOWN

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BN	McGraw, T., Mindich, L. & Frangione, B. Nucleotide sequence of the small double-stranded RNA segment of bacteriophage phi 6: novel mechanism of natural translational control. <i>J Virol</i> 1986, 58(1), 142-151.	
	BO	Menard, R., Sansonetti, P.J. & Parsot, C. Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells. <i>J Bacteriol</i> 1993, 175(18), 5899-5906.	
	BP	Mindich, L. Bacteriophage phi 6: a unique virus having a lipid-containing membrane and a genome composed of three dsRNA segments. <i>Adv Virus Res</i> 1988, 35, 137-176.	
	BQ	Mindich, L., Nemhauser, I., Gottlieb, P. <i>et al.</i> Nucleotide sequence of the large double-stranded RNA segment of bacteriophage phi 6: genes specifying the viral replicase and transcriptase. <i>J Virol</i> 1988, 62(4), 1180-1185.	
	BR	Mindich, L. Precise packaging of the three genomic segments of the double-stranded-RNA bacteriophage phi6. <i>Microbiol. Mol. Biol. Rev.</i> 1999, 63(1), 149-160.	
	BS	Mindich, L., Qiao, X., Qiao, J., Onodera, S., Romantschuk, M. & Hoogstraten, D. Isolation of additional bacteriophages with genomes of segmented double-stranded RNA. <i>J Bacteriol</i> 1999, 181(15), 4505-4508.	
	BT	Mindich, L., Qiao, X., Onodera, S., Gottlieb, P. & Strassman, J. Heterologous recombination in the double-stranded RNA bacteriophage phi 6. <i>J Virol</i> 1992, 66(5), 2605-2610.	
	BU	Mindich, L., Qiao, X. & Qiao, J. Packaging of multiple copies of reduced-size genomic segments by bacteriophage phi 6. <i>Virology</i> 1995, 212(1), 213-217.	
	BV	Moore, J.P., Willey, R.L., Lewis, G.K., Robinson, J. & Sodroski, J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. <i>J. Virol.</i> 1994, 68(11), 6836-6847.	
Examiner signature		Date Considered	

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

- 4 Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).



**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 7 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BW	Moore, J.P., Thali, M., Jameson, B.A. <i>et al.</i> Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. <i>J. Virol.</i> 1993, 67(8), 4785-4796.	
	BX	Murthy, K.K., Cobb, E.K., Rouse, S.R., Lunceford, S.M., Johnson, D.E. & Galvan, A.R. Correlates of protective immunity against HIV-1 infection in immunized chimpanzees. <i>Immunol. Lett.</i> 1996, 51(1-2), 121-124.	
	BY	Okahashi, N., Yamamoto, M., Vancott, J.L. <i>et al.</i> Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant <i>Salmonella</i> strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. <i>Infect. Immun.</i> 1996, 64(5), 1516-1525.	
	BZ	Olkkonen, V.M. & Bamford, D.H. The nucleocapsid of the lipid-containing double-stranded RNA bacteriophage phi 6 contains a protein skeleton consisting of a single polypeptide species. <i>J Virol</i> 1987, 61(8), 2362-2367.	
	CA	Olkkonen, V.M., Gottlieb, P., Strassman, J., Qiao, X.Y., Bamford, D.H. & Mindich, L. In vitro assembly of infectious nucleocapsids of bacteriophage phi 6: formation of a recombinant double-stranded RNA virus. <i>Proc. Natl. Acad. Sci.</i> 1990, 87(23), 9173-9177.	
	CB	Onodera, S., Qiao, X., Qiao, J. & Mindich, L. Directed changes in the number of double-stranded RNA genomic segments in bacteriophage phi6. <i>Proc Natl Acad Sci USA</i> 1998, 95(7), 3920-3924.	
	CC	Onodera, S., Olkkonen, V.M., Gottlieb, P. <i>et al.</i> Construction of a transducing virus from double-stranded RNA bacteriophage phi6: establishment of carrier states in host cells. <i>J Virol</i> 1992, 66(1), 190-196.	
Examiner signature		Date Considered	

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of

relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

<p align="center"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p align="center">Sheet 8 of 11</p>	<i>COMPLETE IF KNOWN</i>	
	Application Number	10/525,702
	Filing Date	February 18, 2005
	First Named Inventor	HONE, David
	Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	4115-178

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CD	Pal, R., DeVico, A., Rittenhouse, S. & Sarngadharan, M.G. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A. <i>Virology</i> 1993, 194(2), 833-837.	
	CE	Parks, G.D., Duke, G.M. & Palmenberg, A.C. Encephalomyocarditis virus 3C protease: efficient cell-free expression from clones which link viral 5' noncoding sequences to the P3 region. <i>J. Virol.</i> 1986, 60(2), 376-384.	
	CF	Parren, P.W., Ditzel, H.J., Gulizia, R.J. <i>et al.</i> Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. <i>Aids</i> 1995, 9(6), F1-6.	
	CG	Phenix, K.V., Wark, K., Luke, C.J. <i>et al.</i> Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. <i>Vaccine</i> 2001, 19(23-24), 3116-3123.	
	CH	Pincus, S.H., Wehrly, K., Cole, R. <i>et al.</i> In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. <i>AIDS Res. Hum. Retrovir.</i> 1996, 12(11), 1041-1051.	
	CI	Price, B.M., Liner, A.L., Park, S., Leppla, S.H., Mateczun, A. & Galloway, D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. <i>Infect. Immun.</i> 2001, 69(7), 4509-4515.	
	CJ	Pushko, P., Parker, M., Ludwig, G.V., Davis, N.L., Johnston, R.E. & Smith, J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. <i>Virology</i> 1997, 239(2), 389-401.	
Examiner signature			Date Considered 

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

- 2 Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 9 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CK	Putkonen, P., Thorstensson, R., Ghavamzadeh, L. <i>et al.</i> Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. <i>Nature</i> 1991, 352(6334), 436-438.	
	CL	Qiao, X., Casini, G., Qiao, J. & Mindich, L. In vitro packaging of individual genomic segments of bacteriophage phi 6 RNA: serial dependence relationships. <i>J Virol</i> 1995, 69(5), 2926-2931.	
	CM	Qiao, X., Qiao, J., Onodera, S. & Mindich, L. Characterization of phi 13, a bacteriophage related to phi 6 and containing three dsRNA genomic segments. <i>Virology</i> 2000, 275(1), 218-224	
	CN	Qiao, X., Qiao, J. & Mindich, L. An in vitro system for the investigation of heterologous RNA recombination. <i>Virology</i> 1997, 227(1), 103-110.	
	CO	Sands, J.A. & Lowlicht, R.A. Temporal origin of viral phospholipids of the enveloped bacteriophage phi 6. <i>Can J Microbiol</i> 1976, 22(2), 154-158.	
	CP	Shata, M.T. & Hone, D.M. Vaccination of a <i>Shigella</i> DNA vaccine vector induces antigen-specific CD8 <sup>+</sup> T-cells and antiviral protective immunity. <i>J. Virol.</i> 2001, 75(20), 9665-9670.	
	CQ	Shata, M.T., Reitz, Jr., M.S., DeVico, A.L., Lewis, G.K. & Hone, D.M. Mucosal and systemic HIV-1 Env-specific CD8 <sup>+</sup> T-cells develop after intragastric vaccination with a <i>Salmonella</i> Env DNA vaccine vector, <i>Vaccine</i> 2002, 20, 623-629.	
	CR	Sinclair, J.F., Tzagoloff, A., Levine, D. & Mindich, L. Proteins of bacteriophage phi6. <i>J Virol</i> 1975, 16(3), 685-695.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 10 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CS	Srinivasan, J., Tinge, S., Wright, R., Herr, J.C. & Curtiss, R., 3rd. Oral immunization with attenuated <i>Salmonella</i> expressing human sperm antigen induces antibodies in serum and the reproductive tract. <i>Biol. Reprod.</i> 1995, 53(2), 462-471.	
	CT	Staats, H.F., Nichols, W.G. & Palker, T.J. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). <i>J. Immunol.</i> 1996, 157(1), 462-472.	
	CU	Sullivan, N., Sun, Y., Sattentau, Q. <i>et al.</i> CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. <i>J. Virol.</i> 1998, 72(6), 4694-4703.	
	CV	Van Etten, J.L., Vidaver, A.K., Koski, R.K. & Semancik, J.S. RNA polymerase activity associated with bacteriophage phi 6. <i>J Virol</i> 1973, 12(3), 464-471	
	CW	Van Etten, J.L., Vidaver, A.K., Koski, R.K. & Burnett, J.P. Base composition and hybridization studies of the three double-stranded RNA segments of bacteriophage phi 6. <i>J Virol</i> 1974, 13(6), 1254-1262.	
	CX	Withoff, S., Glazenburg, K.L., van Veen, M.L. <i>et al.</i> Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines. <i>Gene Ther</i> 2001, 8(20), 1515-1523.	
	CY	Wu, S., Pascual, D.W., Lewis, G.K. & Hone, D.M. Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a <i>Salmonella</i> -HIV vector. <i>AIDS Res. Hum. Retrovir.</i> 1997, 13(14), 1187-1194.	
	CZ	Wu, S., Pascual, D.W., VanCott, J.L. <i>et al.</i> Immune responses to novel <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic <i>E. coli</i> in the absence of the CFA/I positive regulator <i>cfaR</i> . <i>Infect. Immun.</i> 1995, 63(12), 4933-4938.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3).

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 11 of 11

*COMPLETE IF KNOWN*

Application Number	10/525,702
Filing Date	February 18, 2005
First Named Inventor	HONE, David
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4115-178

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	DA	Xu-Amano, J., Kiyono, H., Jackson, R.J. <i>et al.</i> Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. <i>J. Exp. Med.</i> 1993, 178(4), 1309-1320.	
	DB	Yamamoto, S., Kiyono, H., Yamamoto, M. <i>et al.</i> A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. <i>Proc. Natl. Acad. Sci.</i> 1997, 94(10), 5267-5272.	
	DC	Zhou, X., Berglund, P., Rhodes, G., Parker, S.E., Jondal, M. & Liljestrom, P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. <i>Vaccine</i> 1994, 12(16), 1510-1514.	
Examiner signature			Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).